|Description||AG-494 is a EGFR (epidermal growth factor receptor) kinase inhibitor with IC50 value of 0.7 μM. It is selective over ErbB2, PDGFR and insulin receptor kinase (IC50 values are 42, 6 and > 100 μM respectively). AG-494 tyrphostin also can block Cdk2 activation.|
|Synonyms||alpha-Cyano-(3,4-dihydroxy)-N-phenylcinnamide; Tyrphostin AG-494; Tyrphostin B48|
|Solubility||Soluble to 5 mM in ethanol and to 50 mM in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...
Naquotinib is a irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activitywith ...
BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.
EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mut...
PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung can...
Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. AZD8931 binds to and inhibits erbB tyro...
CO-1686 hydrobromide is the hydrobromide salt form of CO-1686. CO-1686, also called as Rociletinib, is an oral tyrosine kinase inhibitor that irreversibly and s...
TPC-064 is a novel mutant-selective inhibitor of EGFR, which plays a role in NSCLC and therefore becomes a key target for cancer therapy. TPC-064 can selectivel...
AV-412 is a dual EGFR/ErbB2 kinase inhibitor. It completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 ...
PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...
Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA M...
CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring t...
Selatinib is a Epidermal growth factor receptor(EGFR) and ERbB-2 receptor antagonist as an analog of the quinazoline lapatinib with potential antineoplastic act...
This active molecular is an irreversible EGFR ( epidermal growth factor receptor ) tyrosine kinase inhibitor. Transtinib shows good anti-proliferative activity ...
AZD9291DA HCl salt
AZD9291-DA is a des acryl analogue of AZD9291, which is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients ...
AG 555 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (IC50 = 0.7 μM) with 50-fold and >140-fold selectivity over ErbB2 and insulin rec...
EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...